Efficacy of Semaglutide in Glycemic Control, Weight Loss, and Improving Lipidogram- Role of Baseline Vitamin D Levels

Sponsor
Hillel Yaffe Medical Center
Study ID
NCT07043361
Status
Completed

Conditions

  • Metabolic Disease

Eligibility Criteria

Sex
ALL
Age
18 Years - 80 Years
Healthy Volunteers
Not accepted

Interventions

  • semaglutide — DRUG
    testing the effect of baseline vitamin D on metabolic effects of semaglutide

Study Details

Objective: Semaglutide, a glucagon-like peptide-1 receptor agonist, is an established therapy for type 2 diabetes (T2D), offering robust glycemic control and weight reduction. Vitamin D has been implicated in metabolic regulation, yet its influence on semaglutide-induced outcomes remains unclear. Research Design and Methods: the investigators conducted a cross-sectional analysis of 5,300 adults with T2D, enrolled in Leumit Health Services, who initiated semaglutide therapy between February 1, 2019, and December 31, 2022. All patients had documented serum 25-hydroxyvitamin D \[25(OH)D\] levels prior to treatment initiation. Metabolic outcomes- including glycemic control (HbA1c), body mass index (BMI), and lipid profile- were assessed at 12 months. Associations between baseline 25(OH)D levels and metabolic changes were evaluated using multivariable regression models, adjusted for demographic and clinical covariates.

Key Dates

Start date
Dec 18, 2023
Status verified
Jun 2025
Primary completion
Dec 21, 2024
Completion
Apr 30, 2025

Study Design

Enrollment
5,300 participants (actual)

Arms

  • Arm: diabetic patients on semaglutide
    we tested the relation between baseline vitamin D levels and metabolic amplification of semaglutide metabolic effects

Primary Outcome Measure

relative weight loss measured by BMI [ Time Frame: 12 months from semaglutide initiation ]

Related Studies